OTCMKTS:EPGNY Epigenomics (EPGNY) Stock Price, News & Analysis → Nvidia’s Quiet $1 Trillion Pivot (From Weiss Ratings) (Ad) Free EPGNY Stock Alerts $2.39 0.00 (0.00%) (As of 04/6/2023) Add Compare Share Share Today's Range$2.39▼$2.3950-Day Range$2.39▼$2.3952-Week Range$2.01▼$2.39VolumeN/AAverage Volume100 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Epigenomics alerts: Email Address Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Epigenomics Stock (OTCMKTS:EPGNY)Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.Read More EPGNY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EPGNY Stock News HeadlinesMarch 14, 2024 | markets.businessinsider.comEQS-News: Epigenomics AG publishes financial results for fiscal year 2023January 31, 2024 | markets.businessinsider.comEQS-News: Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive BoardOctober 10, 2023 | markets.businessinsider.comEQS-Adhoc: Epigenomics AG: Closing of Agreement on the Acquisition of Almost All Assets and Adjustment of Guidance for 2023October 10, 2023 | markets.businessinsider.comEQS-News: Epigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of the Company's Assets and Adjustment of Guidance for 2023September 20, 2023 | finance.yahoo.comCardio Diagnostics Publishes Novel and Scalable Pathways to Enhance Global Coronary Heart Disease Care through Precision Epigenetics in EpigenomicsSeptember 14, 2023 | benzinga.comNew Day Diagnostics Announces Approval of Purchase Agreement by Epigenomics' AG Extraordinary General MeetingAugust 10, 2023 | markets.businessinsider.comEQS-News: Epigenomics AG publishes financial results for the first six months 2023July 24, 2023 | markets.businessinsider.comEQS-News: Epigenomics AG Announces Successful Agreement on the Acquisition of Significant AssetsJuly 24, 2023 | finance.yahoo.comNew Day Diagnostics LLC Reinforces Commitment to Early Cancer Intervention with Its intention to Acquire the Assets of Epigenomics AGJuly 3, 2023 | finance.yahoo.comEstimating The Intrinsic Value Of Epigenomics AG (ETR:ECX1)June 12, 2023 | marketwatch.comEpigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5 MlnMay 19, 2023 | uk.news.yahoo.comEpigenomics AG: Member of the Executive Board and Chief Scientific Officer Andrew Lukowiak ResignsMay 19, 2023 | markets.businessinsider.comEQS-News: Epigenomics AG: Member of the Executive Board and Chief Scientific Officer Andrew Lukowiak ResignsApril 13, 2023 | uk.finance.yahoo.comEpigenomics AG: Chief Executive Officer Greg Hamilton ResignsApril 12, 2023 | markets.businessinsider.comEQS-Adhoc: Epigenomics AG: Changes in the ManagementApril 12, 2023 | markets.businessinsider.comEQS-News: Epigenomics AG: Chief Executive Officer Greg Hamilton ResignsMarch 20, 2023 | uk.finance.yahoo.comEpigenomics AG: Adjustment of guidance and notice of loss pursuant to sec. 92 para. 1 of the German Stock Corporation ActMarch 14, 2023 | benzinga.comSample Preparation in Genomics, Proteomics, and Epigenomics Global Market Report 2023: Increased R&D Spending in Developing Economies Boosts SectorMarch 10, 2023 | uk.finance.yahoo.comEpigenomics AG: Revocation of admission to the Prime Standard (sub-segment of the regulated market with additional post-admission obligations)February 21, 2023 | marketwatch.comPersonalized Medicine and Epigenomics Market Capitalizing on Market Growth: Essential Insights from Our Latest Research ReportJanuary 27, 2023 | uk.finance.yahoo.comEpigenomics AG: Resignation of Supervisory Board Chairman Heino von ProndzynskiJanuary 27, 2023 | markets.businessinsider.comEQS-News: Epigenomics AG: Resignation of Supervisory Board Chairman Heino von ProndzynskiDecember 23, 2022 | markets.businessinsider.comEQS-News: Pareto Securities AS publishes buy recommendation for Epigenomics AG shareDecember 21, 2022 | markets.businessinsider.comEQS-Adhoc: Epigenomics AG: Further raise of earnings guidance for the current fiscal year 2022December 14, 2022 | markets.businessinsider.comEQS-Adhoc: Epigenomics Releases Performance Data on Next Generation TestSee More Headlines Receive EPGNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Epigenomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolOTCMKTS:EPGNY CUSIPN/A CIKN/A Webwww.epigenomics.com Phone(493) 024-3450FaxN/AEmployees32Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Gregory K. Hamilton (Age 52)CEO & Member of the Exec. Board Comp: $828.44kDr. Andrew A. Lukowiak Ph.D. (Age 50)Pres & Chief Scientific Officer Comp: $387.44kMr. Jens Ravens (Age 52)CFO & Member of Exec. Board Frederic HilkeInvestor Relations OfficerDr. Noel Thomas DohenyChief Exec. Officer of Epigenomics Inc.Key CompetitorsANGLEOTCMKTS:ANPCYbioAffinity TechnologiesNASDAQ:BIAFWEternity HealthcareOTCMKTS:ETAHIntegral DiagnosticsOTCMKTS:ITGDFIntegrated DiagnosticsOTCMKTS:IDGXFView All Competitors EPGNY Stock Analysis - Frequently Asked Questions How have EPGNY shares performed in 2024? Epigenomics' stock was trading at $2.39 at the beginning of the year. Since then, EPGNY stock has increased by 0.0% and is now trading at $2.39. View the best growth stocks for 2024 here. How do I buy shares of Epigenomics? Shares of EPGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:EPGNY) was last updated on 6/4/2024 by MarketBeat.com Staff From Our PartnersNvidia’s Quiet $1 Trillion PivotWeiss RatingsThe Only Energy Play You Should Be Looking AtWealthpin ProClaim Your Complimentary Bitcoin RewardCrypto Swap Profits[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaElon Musk’s Final Masterpiece: “X-9840”Paradigm PressPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyBUY ALERT: Tiny tech play partners with US governmentStansberry ResearchCollapse of the Petrodollar Colonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Epigenomics AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.